학술논문
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Document Type
Article
Author
Saura, Cristina ; Hlauschek, Dominik; Oliveira, Mafalda; Zardavas, Dimitrios; Jallitsch-Halper, Anita; de la Peña, Lorena; Nuciforo, Paolo; Ballestrero, Alberto; Dubsky, Peter; Lombard, Janine M; Vuylsteke, Peter; Castaneda, Carlos A; Colleoni, Marco; Santos Borges, Giuliano; Ciruelos, Eva; Fornier, Monica; Boer, Katalin; Bardia, Aditya; Wilson, Timothy R; Stout, Thomas J; Hsu, Jerry Y; Shi, Yi; Piccart, Martine; Gnant, Michael; Baselga, José; de Azambuja, Evandro
Source
In The Lancet Oncology September 2019 20(9):1226-1238
Subject
Language
ISSN
1470-2045